Skip to main content

Advertisement

Table 6 Overall response rate and PFS in 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Berlin 2002 162 Gemcitabine 5.6 -- 2.2  
   160 Gemcitabine + 5-FU (bolus) 6.9   3.4 0.022
Riess 2005 238 Gemcitabine 7.2 -- 3.5 0.44
   235 Gemcitabine + 5-FU (infusional) 4.8   3.5  
DiCostanzo 2005 48 Gemcitabine 8 -- 3.5 --
   43 Gemcitabine + 5-FU (CI) 11   4.5  
Scheithauer 2003 42 Gemcitabine 14 -- 4.0 --
   41 Gemcitabine + Capecitabine 17   5.1  
Herrmann 2005 159 Gemcitabine 7.9 -- 4.0 0.207
   160 Gemcitabine + Capecitabine 10.1   4.8  
Cunningham 2005 266 Gemcitabine 7.1 0.008 na na
   267 Gemcitabine + Capecitabine 14.2   na  
  1. ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; na = data not available; CI = continuous infusion; 5-FU = 5-fluorouracil;